Díaz Leonardo, Gil Alain Chaple, Marttens Alfredo Von, Basualdo Javier, Sotomayor Claudio, Becerra Alexis Vera, Beltrán Víctor, Jorquera Gilbert, Caviedes Rodrigo, Fernández Eduardo
Department of Prosthodontics, Faculty of Dentistry, University of Chile, Santiago, Chile; PhD Student, Department of Stomatology, Faculty of Dentistry, Universidad de Sevilla, Sevilla, Spain; Perioplastic Institute, Santiago, Chile.
Universidad Autónoma de Chile, Facultad de Ciencias de la Salud, Santiago, Chile.
Photodiagnosis Photodyn Ther. 2025 May 3;53:104618. doi: 10.1016/j.pdpdt.2025.104618.
Intravascular Laser Irradiation of Blood (ILIB) is a systemic application of photobiomodulation therapy (PBMT), proposed to modulate oxidative stress, inflammation, and mitochondrial function. Although its clinical use is expanding across various medical conditions, a consolidated evaluation of its therapeutic relevance remains lacking.
This review aimed to synthesize available evidence from randomized controlled trials (RCTs) on the clinical efficacy and safety of ILIB, with particular focus on outcomes related to pain, inflammation, oxidative stress, and quality of life.
a narrative literature review guided by PRISMA principles and the PROPS contextual framework. Eight RCTs involving 340 participants were identified through searches in five electronic databases and gray literature. Studies were eligible if they investigated ILIB-via intravascular or transcutaneous application-and reported clinical or biochemical outcomes compared to sham, placebo, or standard care.
Eight RCTs comprising 340 participants were included, addressing conditions such as cardiovascular disease, diabetic neuropathy, osteoarthritis, spinal cord injury, chronic endometritis, cellulite, and pediatric dental anxiety. ILIB demonstrated consistent reductions in pain (30-55 %), inflammatory cytokines (e.g., IL-6, TNF-α), and oxidative stress markers, along with significant improvements in mitochondrial activity and quality-of-life indicators (SF-36, WOMAC). No serious adverse events were reported. RoB analysis indicated four studies with low risk and four with some concerns.
ILIB appears to be a safe and promising intervention with systemic biological effects and multidimensional clinical benefits. Future clinical research should prioritize standardized dosimetry protocols and long-term, patient-centered outcomes to guide broader integration into evidence-based care.
血管内激光血液照射（ILIB）是光生物调节疗法（PBMT）的一种全身性应用，旨在调节氧化应激、炎症和线粒体功能。尽管其临床应用正在扩展到各种医疗状况，但对其治疗相关性仍缺乏综合评估。
本综述旨在综合随机对照试验（RCT）中关于ILIB临床疗效和安全性的现有证据，特别关注与疼痛、炎症、氧化应激和生活质量相关的结果。
一项遵循PRISMA原则和PROPS背景框架的叙述性文献综述。通过在五个电子数据库和灰色文献中检索，确定了八项涉及340名参与者的RCT。如果研究通过血管内或经皮应用研究ILIB，并报告与假手术、安慰剂或标准护理相比的临床或生化结果，则符合纳入标准。
纳入了八项包含340名参与者的RCT，涉及心血管疾病、糖尿病神经病变、骨关节炎、脊髓损伤、慢性子宫内膜炎、蜂窝组织炎和儿童牙科焦虑症等病症。ILIB在疼痛（降低30 - 55%）、炎性细胞因子（如IL - 6、TNF - α）和氧化应激标志物方面表现出持续降低，同时线粒体活性和生活质量指标（SF - 36、WOMAC）有显著改善。未报告严重不良事件。偏倚风险分析表明四项研究风险较低，四项存在一些问题。
ILIB似乎是一种安全且有前景的干预措施，具有全身性生物学效应和多维度临床益处。未来的临床研究应优先制定标准化剂量方案以及以患者为中心的长期结果，以指导更广泛地纳入循证护理。
